This review discusses progress in understanding the impact of immune tolerance on inducing broadly neutralizing antibodies (bnAbs), and how such knowledge can be incorporated into novel immunization approaches.
INTRODUCTION
Despite major advances in treatment and preventive measures, the HIV-1 pandemic has not slowed down significantly, with now over 35 million people infected. Thus, the development of a transmission-preventive HIV-1 vaccine is crucial, but continues to be elusive. Why is this? A correlate of most successful viral vaccines is generating potently neutralizing antibodies [1] . HIV-1, however, differs from other viruses for which Food and Drug Administration-approved vaccines have been made because as an integrating, rapidly mutating retrovirus, it is resistant to immune responses upon establishment of a latently-infected pool of CD4 þ T-cells [2] . Therefore, it is critical for an HIV vaccine to rapidly induce neutralizing antibodies reactive to a broad spectrum of HIV-1 strains [broadly neutralizing antibodies (bnAbs)]. Studies demonstrating robust protection by passive infusion of bnAbs preceding SHIV challenge in rhesus macaques [3, 4] or their transduction in humanized mice prior to HIV-1 infection [5] lend support to this strategy. Furthermore, serum profiling of HIV-1 chronically infected subjects reveal that bnAbs can eventually develop, although only years after transmission, too late to avert disease course, and only in a minority of patients [6] [7] [8] [9] .
Unfortunately, efforts to elicit significant titers of bnAbs by immunization have failed. Thus, identifying the obstacles impeding bnAb induction by existing immunization regimens and devising strategies capable of overcoming them is key to HIV-1 vaccine development. Defining the origins and precise characteristics of bnAbs from HIV-1 infected individuals has been facilitated by comprehensive serum profiling assays, improved antigen-specific memory B-cell sorting [10, 11] and culture methodologies [12, 13] , and by high-throughput recombinant antibody cloning techniques [14, 15] . These efforts have led to the discovery of new bnAbs with remarkable breadth/potency, and helped define structural characteristics of four vulnerable areas of the HIV-1 Envelope (Env) targeted by bnAbs: the gp120 CD4-binding site (CD4bs), the gp41 membrane proximal external region (MPER), and two novel peptide-glycan epitope-rich regions in either the gp120 V1/V2 or V3 hypervariable loops of gp120 (reviewed in [16 && ]). Furthermore, it is now known that bnAbs targeting more than one region are frequently co-produced in some individuals [8, 17, 18] , passively administered combinations of two bnAbs to distinct targets can confer near-complete breadth [19, 20] , and increased selection for escape mutants occur when individual bnAb lineages are produced during infection [21 && ]. These data thus suggest that immunization regimens capable of eliciting more than one class of bnAb may not only be a desirable, but possibly necessary.
Despite this remarkable progress, the field's best efforts at engineering immunogens capable of presenting Env epitopes remain unsuccessful at inducing bnAbs [16 && ]. Thus, it is becoming clear that traditional 'structure-based' approaches (see [2, [22] [23] [24] [25] [26] [27] ) will likely not solve the HIV-1 vaccine problem alone. Attention has now shifted to the host for insight into why bnAbs are difficult to elicit. This review provides a perspective on the potential association of bnAbs with self-reactivity and its role in generating subdominant bnAb responses to vaccines. It is not exhaustive; we will not cover structural considerations, which have been reviewed elsewhere [16 && , [28] [29] [30] [31] [32] . Furthermore, as all bnAbs isolated thus far originate from chronically-infected individuals, wherein secondary B-cell dysregulation/dysfunction effects may have impacted the magnitude/quality of bnAb responses (reviewed in [33 & ]), we will focus on host factors we predict impact bnAb production not only during infection, but also in vaccination of healthy individuals.
AUTOREACTIVITY, POLYREACTIVITY, AND OTHER UNUSUAL BNAB TRAITS ASSOCIATED WITH TOLERANCE INDUCTION
Between 1993 and 2009, only a handful of bnAbs were identified, of which only three, 2F5, 4E10, and 2G12, were isolated directly from chronically infected patients. In 2005, two of these, 2F5 and 4E10, specific for linear, adjacent epitopes in the MPER, were reported to have elongated, hydrophobic heavy chain complementarity-determining region 3 (HCDR3) residues, and to exhibit poly/ autoreactivity in vitro [34] . Because both sets of traits are potential predictors of negative B-cell selection, based on numerous studies (reviewed in [35] ), this led to the hypothesis that bnAbs like 2F5 and 4E10 are rarely generated because the B cells, which produce them are subjected to immune tolerance [36] . A corollary of this hypothesis that bnAbs are more readily generated in autoimmune subjects (with defective tolerance), was also indirectly supported by reports of disproportionate infrequency of systemic lupus erythematosus (SLE) þ subjects with HIV-1 infection [36] [37] [38] [39] [40] [41] .
This hypothesis has been independently investigated by three groups that monitored B-cell development in knock-in mice expressing the original (mutated) VDJ rearrangements of 2F5 and 4E10 [42, 43, 44 && ,45 && ,46 & ]. 2F5/4E10 (VDJ or VDJþVJ) knock-in mice share a striking blockade in immature B-cell generation, a phenotype characteristic of
KEY POINTS
Numerous bnAbs have recently been identified, many of which have unusually long, hydrophobic heavy chain DR3 (HCDR3) regions and/or in-vitro poly/ autoreactivity, traits normally associated with negative B-cell selection.
The exceptional degree of somatic mutation found in all bnAbs isolated thus far suggests their generation via convoluted affinity maturation pathways, which directly or indirectly may result from mimicry of self-antigens by bnAb epitopes.
Knock-in mice of bnAbs targeting the gp41 MPER region have provided evidence that bnAb poly/ autoreactivity can invoke host tolerance controls, which profoundly impact their production. ]. However, as affinity is only one aspect of an autoantigen's ability to effect tolerance [52,53], formal demonstration of these 2F5/4E10 targets as their bona fide self-ligands will require breeding of 2F5/4E10 knockin mice to those with targeted disruptions in their putative self-reactive motifs. In terms of relevance to vaccine development, it will be important to determine the extent to which this kind of self-antigen mimicry limits bnAb generation, and the stage in B-cell development when bnAbs normally acquire tolerizing reactivity. Regarding this latter point, preliminary data suggest that it can occur at any of several checkpoints: bnAbs like 2F5 may be tolerized early in BM B-cell development, since knock-in mice carrying reverted 2F5 BCRs undergo central deletion (Verkoczy L, Haynes BF, unpublished data), whereas others like CH103 and 4E10, whose precursor BCRs lack both bnAb and self-epitope specificity in vitro ([21
&&
,54] and Haynes BF, unpublished data) may acquire tolerizing polyreactivity de novo, in the periphery.
IS THERE A CORRELATION BETWEEN SELF-REACTIVITY OF BNABS AND THEIR UNUSUAL SOMATIC HYPERMUTATION LEVELS?
Over 120 bnAbs have now been identified worldwide ( [10] [11] [12] [13] [14] [15] , reviewed in [16
&&

,55
& ]). Although these bnAbs often have greater breadth and/or potency than those initially isolated, most share predictive traits of negative selection: many share elongated HCDR3s and, as examined by standard in-vitro autoimmune assays, about half exhibit poly-and/or autoreactivity ( Fig. 1a ) [16 && ,56 && ]. Furthermore, from this representative bnAb dataset emerges an additional feature common to all: an exceptionally high degree of somatic hypermutation (SHM)-mediated aa changes in V(D)J rearrangements.
SHM, along with the linked mechanism of BCR affinity-dependent selection, comprise a general 'fine-tuning' process that occurs in germinal centers known as affinity maturation. Affinity maturation is crucial for generating higher-affinity BCRs/secreted antibodies and formation of higher-affinity memory B-cells that confer long-term protection against future infections, the hallmark of secondary B-cell responses. During 'typical' affinity maturation responses, SHM levels increase BCR affinity but can also inadvertently create de-novo self-reactivity, and thus normally plateaus at $5-6%. SHM in excess of that is believed to increase the probability of generating self-reactivity and decrease BCR affinity [60] [61] [62] , resulting in decreased B-cell survival [56 && ,58,59]. Thus, in addition to elongated HCDR3 regions, and poly/autoreactivity, exceptionally high SHM levels in bnAb V(D)J rearrangements (15-48%) represent another trait associated with negative selection.
That all bnAbs identified thus far originate from subjects infected with HIV-1 for 2-4 years suggests such remarkable SHM frequencies are products of disfavored and/or highly convoluted affinity maturation pathways [56 && ]. The reasons for why such complex affinity maturation pathways are generated in chronic infection were unknown until recent examination of clonal bnAb lineages [21 && ,63] suggests a component is a co-evolutionary 'arms race' between viral and host responses. These studies, and recent findings that most experimentally reverted unmutated ancestors of bnAbs lack neutralizing specificity [56 && ,63,64], offer one explanation: extensive modification of precursor BCRs is required to achieve unusual structural requirements for dealing with extensive viral diversification ( Fig. 2a ]. However, the observation that some in-vitro poly/autoreactive bnAbs targeting the same general Env regions tend to be less mutated, relative to their less/nonpolyreactive counterparts (e.g. all MPER bnAbs, relative to 10E8) ( Fig. 1b) . 2b) is that B cells with germline BCRs that bind self-mimicking bnAb epitopes do not contribute to affinity maturation because they are deleted in early development, necessitating recruitment of weakly cross-reactive, mutated B-cell clones to generate bnAbs via affinity maturation. We have proposed a second possibility [67 && ] (Fig. 2c ) that peripheral tolerance drives additional SHM, when bnAb reactivity and selfreactivity are coupled. In this scenario, germinal center-mutated, self-reactive B cells with bnAb specificity initially attempt to escape negative selection by acquiring additional mutations that remove the self-reactivity, but that also inadvertently presumably in an attempt to remove bnAb epitopeassociated self-reactivity. A similar 'affinity reversion/ de-maturation' process has also been documented in ], which demands difficult structural modifications to achieve both framework region flexibility and Env affinity [65 & ]. Note that as shown, B cells with 'acceptable' (nontolerizing) polyreactivity prior to entering the germinal center reaction may be selected for their ability to heteroligate Env [66] , but poly/ self-reactivity may also be acquired during affinity maturation, as in the CH103-CH106 bnAb lineage [21 && ]. In a model in which self-tolerance indirectly impacts excess somatic hypermutation (SHM) [51 && ,56 && ] (b), B cells with bnAb reactivity that mimic host antigens are clonally deleted in early bone marrow development, creating 'holes in the repertoire'. In the absence of competition, weakly cross-reactive clones that already underwent non-Env driven affinity maturation can then participate in additional, Env-driven affinity maturation. Finally, in a model in which self-tolerance directly drives excess SHM [67 && ] (c), B cells that acquire both self and bnAb specificity via affinity maturation use additional SHM/selection to retain bnAb specificity, while removing tolerizing self-reactivity. Such a process would assume close, but not complete bnAb mimicry of self-epitopes. Thus, the degree of additional selection/SHM would be proportional to how closely a particular bnAb epitope mimics selfantigen(s). Note that these hypotheses are not mutually exclusive: for example, the 'tolerance-based' models shown in (b. c) are shown in combination with the 'standard' model, depicted in (a).
the hen egg lysozyme (HEL) knock-in model (Sabouri Z, Goodnow CC, personal communication).
EXAMINING THE EXTENT TO WHICH BNAB LINEAGES ARE UNDER HOST TOLERANCE CONTROLS
Given that all bnAbs identified thus far have at least one of three traits associated with negative selection (Fig. 1) , another emerging consideration for vaccine strategies is understanding how often host tolerance limits bnAb production, namely, do they limit all MPER þ bnAb lineages, to what extent are bnAb lineages targeting other Env regions predisposed to such mechanisms, what percentage of these target Env epitopes mimick host structures and finally, can such host controls be safely overcome by immunization? In this regard, understanding how reliably the two bnAb traits most associated with tolerance controls, in-vitro autoreactivity (that is, binding to one or more host/self-antigens) and polyreactivity (degenerate binding to multiple distinct antigens) as measured in common in vitro clinical assays [14, 34] can predict in-vivo tolerizing effects, is thus critical. Reassuringly, such in-vitro poly/autoreactivities exhibit reasonable concordance with immune tolerance, as suggested by the fact that in-vitro poly/ autoreactivity of the normal human repertoire progressively wanes at developmental stages coinciding with previously defined tolerance checkpoints in mice [14] . However, it is noteworthy that in-vitro poly/ autoreactivity assays can sometimes yield both 'false positives' and 'false negatives'. The former can occur because BCR/Ab in-vitro reactivities to autoantigens are not reflective of those capable of invoking tolerance at physiologically relevant sites of B-cell encounter (reviewed in [51 && ]). Indeed, $15-20% of the mature T-dependent B2 population exhibit such 'acceptable' in-vitro poly/autoreactivity in healthy individuals' repertoires, it may be fairly common [14] . In addition, a large proportion of other B-cell subsets (that is MZ, B-1) [69, 70] , recently shown to harbor specificities resembling those of some bnAbs [71] , also exhibit in-vitro poly/autoreactivity. 'False negatives' can result from technical inter or intra-assay variation between laboratories. For example, the bnAb 10E8, initially reported to lack poly/autoreactivity measured by common assays [57] , has strong affinity for a ubiquitous human protein, when detected in protein microarrays (Liu Y, Yang G, Kelsoe G, et al. unpublished data), and has also been reported to exhibit functionally relevant lipid reactivity [72 & ]. Furthermore, some relevant autoantigens could escape detection by existing technologies if they are tissue/cell-restricted, like insulin B-islets in the pancreas or because BCR/Ab affinities too low to be detected in vitro may effect tolerance mechanisms in vivo [53] . Finally, 'false negatives' could also result from the atypical biology of bnAbs with exceptionally high SHM, which, as products of bnAb lineages whose other bnAb clonal members [11] and/or precursors exhibit prevalent self-reactivity, could represent nonautoreactive 'snapshots'.
Ultimately, the gold standard for confirming the tolerizing effects of a given bnAb (or its lineage members') in-vitro poly/autoreactivity measurements, is gene targeting of its/their V(D)J rearrangements. The power of the knock-in approach is evident in the in-vivo evaluation of 4E10, 2F5 && ]. However, as b12 was generated via phage display, it remains to be seen whether any bnAbs from naturally derived HC/LC chain pairs represent 'false positives' like notable exceptions in the general B-cell literature [74, 75] , and conversely, whether candidate 'false negative' bnAbs, like 10E81, in fact do effect host tolerance controls in vivo. Higher-throughput knock-in approaches, based on recombination activating gene (RAG) blastocyst complementation [76] in which bnAb V(D)J rearrangements could be rapidly inserted, may facilitate this type of analysis. Finally, another independent, potentially fruitful avenue to exploring the prevalence of tolerance controls on bnAb production is examining frequencies and spectra of bnAbs produced by autoimmune patients. The first example of such an analysis is recent characterization of CH98, a CD4bs-specific bnAb isolated from an SLE patient [77] .
FUNCTIONAL AND PRACTICAL ASPECTS OF BNAB TRAITS ASSOCIATED WITH NEGATIVE SELECTION
Each of the above-mentioned traits of bnAbs are paradoxical because although they may predispose bnAbs to host tolerance controls, they may also be critical in conferring their function. Below, we discuss the potential practical relevance of each trait for vaccine development.
bnAb polyreactivity may have both general and specific relevance. General polyreactivity of Envspecific antibodies may increase their overall affinity via heteroligation [66] , a process proposed for dealing with the low density of Env trimer spikes found on HIV-1 [78, 79] . An elegant example of this is the structural analysis of bound 21c, a polyreactive Env Ab, which suggests interaction with not only its expected CD4i epitope, but also an adjacent CD4 receptor [80] . Regarding bnAb function specifically, the lipid polyreactivities of 2F5, 4E10, 10E8, and m66 are believed to be an essential part of a general neutralization mechanism for all MPERspecific bnAbs, in which initial low-affinity contacts with the viral lipid membrane may extract lipidimmersed critical residues, thus allowing subsequent high-affinity interactions with exposed MPER epitopes [72 & , [81] [82] [83] [84] . There is growing consensus that for MPER-based vaccine strategies, appropriate presentation of 2F5/4E10 minimal peptide epitope in lipid membranes is required [85] [86] [87] [88] . Indeed, in 2F5 and 4E10 knock-in mice, only immunization regimens in which 4E10/2F5's neutralization epitopes are presented in virosomes, and in the presence of the lipid component/TLR agonist MPLA, can elicit robust serum bnAb responses [89] .
With respect to bnAb autoreactivity, this trait merits practical considerations only if a bnAb's relevant (tolerizing) self-antigen(s) exhibits considerable structural overlap with its neutralization epitope, as is likely for bnAbs targeting the 2F5 epitope [43,44 && ,51 && ]. In such instances, a key question is whether vaccines can trigger either residual anergic B cells (that retain both bnAb specificity and self-reactivity), or more ideally, rare peripheral 'escape' variants (which have de-coupled self-reactivity and bnAb specificity). Although it remains to be determined whether such latter clones exist, evidence for the former is suggested by the coincident generation of 2F5-like bnAbs and auto-antibodies reported in sera from an HIV-1-infected patient [90] . Importantly, immunization studies in 2F5 knock-in mice demonstrate that such residual anergic B cells can be appropriately activated, thus providing proof-of-principle that their autoreactivity can be overcome by vaccination [67 && ]. Furthermore, concerns about the pathogenicity of eliciting 2F5-like bnAbs are alleviated by passive infusion studies of 4E10, 2F5, or 2G12, which have not shown clinically adverse effects [91] [92] [93] , except anticoagulant-activity for 4E10 [94] , which is consistent with its higher lipid affinity, relative to 2F5 [34] .
With respect to elongated and/or hydrophobic bnAb HCDR3 s, hydrophobic residues appear critical for neutralization-conferring lipid reactivity of all MPER-specific bnAbs examined thus far, including 2F5/4E10 [81, 82, 95, 96] , 10E8 [72 & ] and M66 [84] , but for bnAbs targeting other Env regions, it is unknown whether their hydrophobicities [35] have functional relevance. However, for bnAbs with exceptionally elongated (>25 aa) HCDR3s, such as the V1V2/glycan-specific bnAbs PG9/PG16, this unusual length is required to form the 'hammerhead' structures thought critical for accessing occluded residues found in complex, glycan-masked epitopes [97] . Encouragingly, although the frequencies of B cells bearing exceptionally long HCDR3 regions are severely limited either by preantigenic constraints (HC/LC pairing and N-addition/VDJ recombination events) and/or various tolerance checkpoints (reviewed in [35] ), they nonetheless are present in repertoires of most healthy individuals [98 & ]. High SHM levels in bnAbs represent a potentially more formidable roadblock for vaccination because conventional vaccines cannot recapitulate affinity maturation pathways during infection that generated such mutational levels; existing HIV-1 immunization regimens produce SHM levels (4-5%) more in-line with autologous nAbs [55 & ]. However, the degree to which observed mutations in bnAbs are required for neutralization breadth/potency is unknown, although several recent studies have begun assessing this [ ] leading to the proposal that exceptionally high SHM levels in bnAb FRWs provide structural flexibility. However, two recent in-vitro mutagenesisscanning studies found that only $10-25% of reverted mutations impacted neutralization function for 10E8 and VRCO1 (two of the most mutated bnAbs) [91, 100] . One explanation for the disparate results is that highly mutated bnAbs may result from the stochastic nature of SHM driving numerous rounds of affinity maturation to create the desired combination of mutations that enhance structural flexibility, and epitope-binding affinity. Alternatively, SHM above the minimum required for neutralization may be the result of conflicted selection pressure in germinal centers: negative (for tolerance) and positive (for affinity) (Fig. 2c) . It is also possible that a component of 'excess' SHM found in bnAbs may be related to chronic HIV-1 infection [33 & ] and its potential effects on immune function (see [101, 102] ), as high mutation levels (although not as dramatic as in bnAbs) are also produced in other chronic infection settings like influenza [56 && ,103 & ]. Ultimately, proof-of-concept immunization studies, including those in knock-in mice expressing reverted ancestors/intermediates of individual bnAb clonal lineages, cross-bred to strains with altered SHM levels [104] may provide some insight on this issue.
Assuming a considerable degree of the SHM generated in bnAbs during infection is required during immunization, new vaccine strategies will have to re-create disfavored and/or convoluted affinity maturation pathways that generated such extensive SHM. B-cell lineage design has been recently proposed for this purpose [21 && ,56 && ], an approach aimed to use immunogens that optimally bind a given bnAb lineage's ancestors and affinity maturation intermediates, administered either sequentially (to help 'guide' affinity maturation pathways) or in combination (to mimic HIV-1 diversity). Perhaps the most straightforward and physiological use of this approach involves using the actual Env proteins identified from sampling serial isolates of bnAb lineages generated during infection, to re-create similar pathways by vaccination [21 && ]. However, other variations have also been proposed, involving use of computational and in-vitro selection methodologies to engineer 'super-immunogens' that can bind BCRs of multiple clonal members from bnAb lineages with common epito-
CONCLUSION
Recent studies using knock-in models demonstrate immune tolerance can profoundly limit bnAb induction, and traits associated with negative selection in many recently discovered bnAbs suggest this has relevance for bnAbs at distinct Env targets. Some aspects of tolerance can be overcome, for example immunization of 2F5 knock-in mice demonstrates overcoming deletion/anergy is possible, provided a structurally compatible immunogen is used, and passive infusion studies suggest pathogenicity would not result from their elicitation. Other aspects, like overlap of self-reactivity with bnAb specificity, which may result in inadvertent selection against the latter, may be more problematic. Further examination of the prevalence of this issue across bnAb lineages will benefit from autoantigen discovery/modeling and high-throughput knock-in approaches. Finally, immunoregulatory factors other than immune tolerance that may contribute to subdominance of bnAb responses, including shaping of the initial B-cell repertoire by incidental exogenous antigen exposure [28] , or host genetic determinants like allelic variation of V H segments utilized by bnAb lineages [107] and major histocompatability complex class II-restriction of overlapping CD4 þ T H /bnAb epitopes [108], may also have to be considered for vaccine strategies.
A key for vaccine development will be determining the feasibility of immunization to elicit affinity maturation pathways that can generate breath/ neutralization in various bnAb lineages. The development of novel immunization strategies like B-cell lineage design, more powerful knock-in-based immunization models (expressing limited repertoires of unrearranged germline segments from representative bnAb lineages) to more efficiently probe affinity maturation pathways in vivo, and isolation of new clonal lineages from both infection and immunization settings will be key. Finally, it should be noted that even when only considering the minimally required mutations for neutralization in highly mutated bnAbs like VRC01, vaccination schemes would still have to generate much higher SHM levels than existing regimens can elicit. We therefore submit that bnAbs with relatively less SHM may be more desirable/tractable targets. Collaboration for AIDS Discovery Vaccine Development Center grant from the Bill and Melinda Gates Foundation.
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There are no conflicts of interest to declare. ], reports no/minimal polyreactivity for 4E10 by either HEp-2 IFA or in protein arrays, and proposes low-affinity lipid interactions are mediated nonspecifically, rather than via hydrophobic interactions. These disparities in how in-vitro polyreactivity and lipid-binding are measured and interpreted for similar assays performed in distinct laboratories highlight the difficulties in defining and the importance of standardizing stringency thresholds for performing such assays. Key article reporting the biochemical identification, using immunoprecipitation and protein microarrays, of two highly-conserved, high-affinity host protein targets of 2F5 and 4E10, respectively, the former interestingly contains a motif with perfect sequence identity to the 2F5 neutralization epitope. Using 2F5 and 4E10 as an example, this study also shows how protein arrays can be used to more comprehensively characterize the poly/autoreactivity profiles of bnAbs and outlines affinity threshold criteria as well as appropriate controls for performing this type of analysis.
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